Keyword Analysis & Research: unasyn for klebsiella

therapeuticseducation.org

https://therapeuticseducation.org/sites/therapeuticseducation.org/files/Antibiotic_Sensitivity_FINAL_Nov_2019.pdf

WebCloxacillin and clindamycin typically have less than 40% activity for S.epidermidis, thus usage depends on local susceptibility data Enterococci has two main species - Enterococcus faecalis and Enterococcus faecium; the antibiotics listed are active against E.faecalis, but have limited activity for E.faecium.

DA: 7 PA: 81 MOZ Rank: 65

uptodate.com

https://www.uptodate.com/contents/clinical-features-diagnosis-and-treatment-of-klebsiella-pneumoniae-infection

WebApr 21, 2023 · Klebsiella pneumoniae is a member of the Klebsiella genus of Enterobacteriaceae and belongs to the normal flora of the human mouth and intestine. ... Similarly, in a study of 855 patients with K. pneumoniae liver abscess in Taiwan and 3420 age- and sex-matched controls, ampicillin or amoxicillin use within the …

DA: 14 PA: 88 MOZ Rank: 2

nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK519004/

WebJul 20, 2023 · Objectives: Describe the pathophysiology of Klebsiella. Identify the most common cause of hospital-acquired pneumonia in the United States. Recall patients most likely to get Klebsiella pneumonia. Review the evaluation and treatment of patients with Klebsiella pneumonia and the interprofessional team's … unasyn

unasyn

DA: 60 PA: 41 MOZ Rank: 93

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070759/

WebApr 14, 2021 · Here, we review elements of the current status of the epidemiology and the molecular pathogenesis of Kp and explore specific bacterial antigens as potential targets for both prophylactic and therapeutic solutions. Keywords: Klebsiella pneumoniae, anti-microbial resistance, vaccines, monoclonal antibodies.

DA: 58 PA: 28 MOZ Rank: 74

medscape.com

https://emedicine.medscape.com/article/219907-treatment

WebDec 7, 2022 · Treatment of Klebsiella pneumonia has discrepant results. For patients with severe infections, a clinically prudent approach is the use of an initial short course (48-72 h) of combination therapy with an aminoglycoside, followed by a switch to an extended-spectrum cephalosporin when susceptibility is confirmed.

DA: 37 PA: 38 MOZ Rank: 36

pfizermedicalinformation.com

https://www.pfizermedicalinformation.com/unasyn/indications-usage

WebUNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 ...

DA: 24 PA: 33 MOZ Rank: 64

medicinenet.com

https://www.medicinenet.com/unasyn_ampicillin_and_sulbactam/article.htm

WebUnasyn is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below: Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, * Klebsiella spp. * (including K. pneumoniae *), Proteus mirabilis ...

DA: 49 PA: 75 MOZ Rank: 46

hopkinsguides.com

https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540302/all/Klebsiella_species

WebLast updated: November 5, 2021. Klebsiella species answers are found in the Johns Hopkins ABX Guide powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.

DA: 48 PA: 46 MOZ Rank: 59

uptodate.com

https://www.uptodate.com/contents/extended-spectrum-beta-lactamases

WebMar 8, 2024 · Extended-spectrum beta-lactamases (ESBLs) are enzymes that confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam aztreonam. Infections with ESBL-producing organisms have been associated with poor outcomes.

DA: 24 PA: 35 MOZ Rank: 63

pfizermedicalinformation.com

https://www.pfizermedicalinformation.com/unasyn/clinical-pharmacology

WebThe presence of sulbactam in the UNASYN formulation effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibacterials.

DA: 23 PA: 17 MOZ Rank: 89